Editing Vertex Pharmaceuticals Incorporated (section)

== Main Competition ==

=== Yumanity Therapeutics: ===
Valued at $19.5 million, revenue for FY 2022 $2 million and net income $63.4 million.

Yumanity Therapeutics, previously known as Proteostasis Therapeutics, is an active biopharmaceutical company based in Boston, MA, US, founded in 2014. The company focuses on developing therapeutics to address diseases resulting from an imbalance in the proteostasis network. Its specialization includes medicines for cystic fibrosis and treatments for unfolded protein response dysfunction. As a public company, Yumanity Therapeutics is actively engaged in advancing its mission to provide innovative solutions for these challenging medical conditions.

=== Eloxx Pharmaceuticals: ===
Valued at $17.3 million and net income $36.1 million in 2022

Eloxx Pharmaceuticals is an active clinical-stage biopharmaceutical company with a focus on the discovery, development, and commercialization of compounds to address genetic diseases caused by nonsense mutations. These conditions include Cystic fibrosis, Duchene Muscular Dystrophy, Usher syndrome, Ataxia-telangiectasia, Beta thalassemia, Tay-Sachs Hurler syndrome, and many others. The company's expertise allows for a swift transition from drug discovery programs to clinical drug candidates, building a robust pipeline of molecules specifically designed for various nonsense genetic diseases. Leading the way is ELX-02, the company's flagship compound, presenting a unique opportunity as a potential disease-modifying therapy for these devastating conditions, where effective treatments are currently unavailable. As a public company founded in 2013, Eloxx Pharmaceuticals remains committed to making significant strides in the treatment of genetic diseases and improving patients' lives.

=== 4D Molecular Therapeutics: ===
Valued at $755.2 million, revenue for FY 2022 $3.1 million and net income $107.5 million.

4D Molecular Therapeutics is an active biotechnology company that is dedicated to the development of gene therapy products aimed at curing genetic diseases. Leveraging its innovative Therapeutic Vector Evolution platform, the company has the capability to create adeno-associated virus (AAV) gene therapy vectors. These vectors play a crucial role in delivering therapeutic genes to diseased tissues or organs within the body. As a public company founded in 2013, 4D Molecular Therapeutics is committed to advancing the field of gene therapy and providing potential cures for a range of genetic disorders. With its focus on cutting-edge research and technology, the company aims to make significant strides in the treatment of genetic diseases, ultimately enhancing the lives of patients worldwide. Headquartered in Emeryville, CA, 4D Molecular Therapeutics continues to drive advancements in the biotechnology industry.

=== Arcturus Therapeutics: ===
Valued at $898.xmillion, revenue for FY 2022 $206 million and net income $9.3 million.

Arcturus Therapeutics is an active preclinical drug delivery and nucleic acid medicines company that specializes in developing cutting-edge technologies for RNA and DNA medicines. With a strong focus on innovation, the company is dedicated to advancing the field of nucleic acid therapeutics. Arcturus Therapeutics was formed through a merger between Arcturus Therapeutics and Alcobra, bringing together their expertise and resources to drive groundbreaking advancements in drug delivery and nucleic acid-based treatments. As a public company founded in 2013, Arcturus Therapeutics remains committed to making a significant impact on the medical landscape by providing potential solutions for various diseases through the application of nucleic acid medicines. Headquartered in San Diego, CA, Arcturus Therapeutics continues to lead the way in the development of transformative therapies for patients worldwide.